AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20429852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18382077 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + MV
Number of subjects: 39
Study 18382077 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 39
Study 18382077 — intervention group
Group type: EXPERIMENTAL
Intervention: MV
Number of subjects: 39
Study 18382077 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 39
Study 16045394 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness interventions (3 of them)
Number of subjects: 6
Study 16045394 — intervention group
Group type: COMPARATOR
Intervention: Plausible control exercise
Number of subjects: 6
Study 12008944 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP70‐1 nucleotide 190
Number of subjects: 338
Study 12008944 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP70‐2 nucleotide 1267
Number of subjects: 338
Study 12008944 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP70‐hom nucleotide 2437
Number of subjects: 338
Study 10023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 0.5 mg/kg/day
Number of subjects: 12
Study 10023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1.0 mg/kg/day
Number of subjects: 12
Study 10023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 2.0 mg/kg/day
Number of subjects: 12
Study 10023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (any dose)
Number of subjects: 12
Study 10023867 — intervention group
Group type: COMPARATOR
Intervention: Control (no ASA)
Number of subjects: 12
Study 7802127 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale
Number of subjects: 431
Study 7802127 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-valid questions about fixity of obsessive-compulsive beliefs
Number of subjects: 431
Study 7802127 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 subcategories
Number of subjects: 431
Study 2218873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystgastrostomy
Number of subjects: 98
Study 2218873 — intervention group
Group type: COMPARATOR
Intervention: Cystjejunostomy
Number of subjects: 98
Study 401759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trental 400 (400 mg Pentoxifylline per tablet), 3 tablets daily for 3 months
Number of subjects: 52
Study 401759 — intervention group
Group type: COMPARATOR
Intervention: Comparative formulation (2.4 mg adenosine per tablet), 3 tablets daily for 3 months
Number of subjects: 52
Study 31969713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% spray, 1-2 applications (0.1-0.2 ml) for 8 weeks, containing 5-10 mg of lidocaine
Number of subjects: 150
Study 31969713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol 40% spray), 1-2 applications (0.1-0.2 ml) for 8 weeks
Number of subjects: 150
Study 31196037 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program (12 lessons)
Number of subjects: 6300
Study 31196037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6300
Study 28546852 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg/day for 28 days)
Number of subjects: 4
Study 28546852 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 4
Study 24684297 — intervention group
Group type: EXPERIMENTAL
Intervention: batroxobin with continuous TCD monitoring
Number of subjects: 90
Study 24684297 — intervention group
Group type: COMPARATOR
Intervention: batroxobin without continuous TCD monitoring
Number of subjects: 90
Study 23532686 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA+ER‐DP 25 mg/200 mg BID alone (Treatment A)
Number of subjects: 60
Study 23532686 — intervention group
Group type: COMPARATOR
Intervention: ASA+ER‐DP 25 mg/200 mg BID + omeprazole 80 mg QD (Treatment B)
Number of subjects: 60
Study 23532686 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 80 mg QD alone (Treatment C)
Number of subjects: 60
Study 23532686 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg QD + ASA+ER‐DP 25 mg/200 mg BID (Treatment D)
Number of subjects: 60
Study 19836206 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI)
Number of subjects: 121
Study 19836206 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Ontario Rotator Cuff index (WORC)
Number of subjects: 121
Study 19836206 — intervention group
Group type: COMPARATOR
Intervention: Oxford Shoulder Scale (OSS)
Number of subjects: 121
Study 19071979 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home methadone doses contingent on cocaine‐ and opiate‐negative results (THM)
Number of subjects: 78
Study 19071979 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home methadone doses for cocaine‐ and opiate‐negative results and monetary‐based vouchers contingent on cocaine‐negative urinalysis results (THM + V)
Number of subjects: 78
Study 19071979 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (UC)
Number of subjects: 78
Study 17286121 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion around the scene (viewpoint changes from 40 degrees to 360 degrees in experiment 1; 36 degrees to 180 degrees in experiment 2)
Number of subjects: 0
Study 17286121 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion around the scene (viewpoint changes from 36 degrees to 180 degrees in experiment 2)
Number of subjects: 0
Study 12817520 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg qd
Number of subjects: 0
Study 12817520 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg bid
Number of subjects: 0
Study 12817520 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (5-500 mg single doses and 25-150 mg multiple doses)
Number of subjects: 0
Study 12817520 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (up to 150 mg qd)
Number of subjects: 0
Study 12817520 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 0
Study 11165311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate administration
Number of subjects: 30
Study 11165311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1355618 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone inhalations before fenoterol inhalations
Number of subjects: 40
Study 1355618 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol inhalations
Number of subjects: 40
Study 6516935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy without imagery (RET)
Number of subjects: 59
Study 6516935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy with imagery (REI)
Number of subjects: 59
Study 6516935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy (RET) and Rational-emotive therapy with imagery (REI)
Number of subjects: 59
Study 6516935 — intervention group
Group type: COMPARATOR
Intervention: Relationship-oriented counseling (ROC)
Number of subjects: 59
Study 6516935 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 59
Study 30685386 — intervention group
Group type: EXPERIMENTAL
Intervention: PLWH
Number of subjects: 36
Study 30685386 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 36
Study 30685386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 29765212 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplement, 3.2 g daily for 6 weeks
Number of subjects: 90
Study 29765212 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3.2 g daily for 6 weeks
Number of subjects: 90
Study 27189289 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (6 g/day) for 6 months
Number of subjects: 28
Study 27189289 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 24374936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrillary astrocytes in schizophrenia
Number of subjects: 67
Study 24374936 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemistocytic astrocytes in schizophrenia
Number of subjects: 67
Study 24374936 — intervention group
Group type: COMPARATOR
Intervention: Fibrillary astrocytes in bipolar disorder, major depression, and normal controls
Number of subjects: 67
Study 24374936 — intervention group
Group type: COMPARATOR
Intervention: Gemistocytic astrocytes in bipolar disorder, major depression, and normal controls
Number of subjects: 67
Study 23607203 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (including pre‐ and postoperative irradiation, surgery, adjuvant chemotherapy)
Number of subjects: 296
Study 23607203 — intervention group
Group type: COMPARATOR
Intervention: Surgery with adjuvant chemotherapy
Number of subjects: 296
Study 20105041 — intervention group
Group type: EXPERIMENTAL
Intervention: P1+ (preserved first-phase insulin secretion)
Number of subjects: 20
Study 20105041 — intervention group
Group type: COMPARATOR
Intervention: P1- (no first-phase insulin secretion)
Number of subjects: 20
Study 16257791 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months' androgen deprivation (3.6 mg goserelin subcutaneously every month and 250 mg flutamide orally three times a day)
Number of subjects: 818
Study 16257791 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months' androgen deprivation (same regimen as above)
Number of subjects: 818
Study 16257791 — intervention group
Group type: COMPARATOR
Intervention: No androgen deprivation (radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6.5‐7.0 weeks)
Number of subjects: 818
Study 14717260 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Child Development Program (CCDP)
Number of subjects: 240
Study 14717260 — intervention group
Group type: COMPARATOR
Intervention: Control (families on AFDC)
Number of subjects: 240
Study 9633847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cycles of high-dose chemotherapy with hematopoietic support (colony-stimulating factors and peripheral blood progenitor cells)
Number of subjects: 0
Study 9633847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cycles of high-dose chemotherapy
Number of subjects: 0
Study 7493828 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal brachytherapy (CB) with HDR boost implants (5.5 Gy, 6 Gy, 6.5 Gy)
Number of subjects: 59
Study 7493828 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online planning system for HDR treatment
Number of subjects: 59
Study 1748134 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 251
Study 1748134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 1748134 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Number of subjects: 251
Study 1748134 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse event monitoring system
Number of subjects: 251
Study 6127890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol 20‐200 mg daily (slow‐release tablet preparation)
Number of subjects: 15
Study 6127890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31563406 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT in a swimming pool
Number of subjects: 42
Study 31563406 — intervention group
Group type: COMPARATOR
Intervention: MICT on dry land
Number of subjects: 42
Study 31563406 — intervention group
Group type: COMPARATOR
Intervention: HIIT on dry land
Number of subjects: 42
Study 27254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily)
Number of subjects: 104
Study 27254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 104
Study 27254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily) + Calcium (1200 mg daily)
Number of subjects: 104
Study 27603424 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG monotherapy (Connaught 120 mg, 6 weekly instillations followed by 10 instillations)
Number of subjects: 321
Study 27603424 — intervention group
Group type: COMPARATOR
Intervention: Alternating therapy with mitomycin C (MMC 40 mg, 6 weekly instillations followed by 10 instillations of BCG)
Number of subjects: 321
Study 27603424 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG monotherapy
Number of subjects: 321
Study 27603424 — intervention group
Group type: COMPARATOR
Intervention: Alternating therapy with MMC and BCG
Number of subjects: 321
Study 24478050 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake for 6 weeks
Number of subjects: 44
Study 24478050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no whole-grain intake for 6 weeks)
Number of subjects: 44
Study 22186981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140
Study 22186981 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 20854115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy
Number of subjects: 0
Study 20854115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17209660 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA4Ig)
Number of subjects: 0
Study 15214141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (400 ml, 400 kcal) daily for six months
Number of subjects: 53
Study 15214141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 ml) daily for six months
Number of subjects: 53
Study 15214141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation
Number of subjects: 53
Study 15214141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15214141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with protein‐energy malnutrition
Number of subjects: 53
Study 15214141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without protein‐energy malnutrition
Number of subjects: 53
Study 12043862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumped Diodium‐Nd:YAG laser (5 Hz for 15 s)
Number of subjects: 60
Study 12043862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumped Diodium‐Nd:YAG laser (10 Hz for 15 s)
Number of subjects: 60
Study 12043862 — intervention group
Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 60
Study 9619529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin (doses ranged from a single 25 microg dose to 100 microg every 4 h for 20 h)
Number of subjects: 34
Study 9619529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin
Number of subjects: 34
Study 7655763 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g piracetam i.v. (250 ml infusion over 30 minutes)
Number of subjects: 18
Study 7655763 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g piracetam p.o. (60 ml sirup)
Number of subjects: 18
Study 7655763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2073165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg OD
Number of subjects: 20
Study 2073165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6772199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8
Study 6772199 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 8
Study 6772199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg total)
Number of subjects: 8
Study 6772199 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (400 mg total)
Number of subjects: 8
Study 30488229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation group
Number of subjects: 48
Study 30488229 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmation (control) group
Number of subjects: 48
Study 28523589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating acetaminophen and ibuprofen (acetaminophen 10 mg/kg per dose with shortest interval of 4 h and ibuprofen 10 mg/kg per dose with shortest interval of 6 h; n=158)
Number of subjects: 474
Study 28523589 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen monotherapy (10 mg/kg per dose with shortest interval of 4 h; n=158)
Number of subjects: 474
Study 28523589 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen monotherapy (10 mg/kg per dose with shortest interval of 6 h; n=158)
Number of subjects: 474
Study 25945551 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 1 lpm
Number of subjects: 30
Study 25945551 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 2 lpm
Number of subjects: 30
Study 25945551 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 3 lpm
Number of subjects: 30
Study 23789747 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PCA with tramadol (20 mg) and metoclopramide (1 mg) per bolus
Number of subjects: 60
Study 23789747 — intervention group
Group type: COMPARATOR
Intervention: Postoperative PCA with morphine (1 mg) per bolus
Number of subjects: 60
Study 21298442 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper step (US) transition to 90% estimated lactate threshold
Number of subjects: 7
Study 21298442 — intervention group
Group type: EXPERIMENTAL
Intervention: Full step (FS) transition to 90% estimated lactate threshold
Number of subjects: 7
Study 21298442 — intervention group
Group type: COMPARATOR
Intervention: Lower step (LS) transition to 90% estimated lactate threshold
Number of subjects: 7
Study 18586338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 45852
Study 18586338 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 45852
Study 17347471 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (n=383)
Number of subjects: 765
Study 17347471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=382)
Number of subjects: 765
Study 14990013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Clarithromycin (500 mg twice daily) for 1 week (RAC group)
Number of subjects: 128
Study 14990013 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Metronidazole (400 mg twice daily) for 1 week (RAM group)
Number of subjects: 128
Study 11178222 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 10
Study 11178222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic heat-moisture exchanger (HME)
Number of subjects: 10
Study 11178222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic heat-moisture exchanger (HME)
Number of subjects: 10
Study 9877365 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulins extracted from immunized bovine colostrum (IIBC) 10 g daily for 4 days
Number of subjects: 80
Study 9877365 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation (10 g daily for 4 days)
Number of subjects: 80
Study 7992594 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin on days 1, 3, 5 plus arabinoside cytosine 1‐7/10 plus etoposide 1‐5 (ICE7/10)
Number of subjects: 56
Study 7992594 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin on days 1‐3 plus Ara‐C 1‐7/10 with additional HD Ara‐C if insufficient cytoreduction (3+7+/‐HD)
Number of subjects: 56
Study 2499160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 707
Study 2499160 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 707
Study 939850 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 59
Study 939850 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 59
Study 30770745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic single-fraction radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT)
Number of subjects: 17
Study 30770745 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 17
Study 30770745 — intervention group
Group type: COMPARATOR
Intervention: Optimal supportive care (SC)
Number of subjects: 17
Study 30770745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of resection, post-operative SRS/SFRT and SRS/SFRT to intact lesions
Number of subjects: 17
Study 30770745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical protocol investigating radiotherapy utilization in the last 30 days of life
Number of subjects: 17
Study 27617368 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-related clinician action
Number of subjects: 994
Study 27617368 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting physician with a respiratory issue
Number of subjects: 994
Study 27617368 — intervention group
Group type: EXPERIMENTAL
Intervention: Already prescribed a respiratory medication
Number of subjects: 994
Study 24832954 — intervention group
Group type: EXPERIMENTAL
Intervention: Moms' Empowerment Program (10-session evidence-based intervention)
Number of subjects: 120
Study 24832954 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study 23910581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide therapy (0.006 μg kg(‐1) min(‐1))
Number of subjects: 60
Study 23910581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21142788 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs coinfusion (3-5 × 10(5) cells/kg)
Number of subjects: 55
Study 21142788 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs coinfusion
Number of subjects: 55
Study 21142788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 19695193 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 45
Study 19695193 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 45
Study 17412329 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplement
Number of subjects: 15
Study 17412329 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric casein placebo
Number of subjects: 15
Study 15118618 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol + 100 microg levonorgestrel followed by 7 pill-free days
Number of subjects: 54